AZTAAzenta, Inc.

1. Oct 7, 2026On October 5, 2026, the Board of Directors of Azenta, Inc. (the “Company”) approved, and the Company committed to, a restructuring plan (the “Plan”) within the Company’s Multiomics reportable segment.Exit or disposal costs (restructuring) · Form 8-K
2. Sep 17, 2026Interim President and Chief Executive Officer Compensation As previously disclosed in the Company’s Current Report on Form 8-K filed on August 24, 2026, the Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) appointed Dr. Martin D. Madaus as the Company’s Interim President and Chief Executive Officer …Director or officer change · Form 8-K
3. Sep 4, 2026As previously disclosed in the Company’s Current Report on Form 8-K filed on July 8, 2026, on July 1, 2026, in connection with the completion of the sale by Azenta Germany GmbH, a wholly owned subsidiary of the Company, of the entire issued share capital of B Medical Systems S.à r.l.Regulation FD disclosure · Form 8-K
4. Aug 24, 2026Resignation of President and Chief Executive Officer On August 22, 2026, John P. Marotta resigned as President and Chief Executive Officer of Azenta, Inc. (the “Company”) and as a member of the Company’s Board of Directors (the “Board”), effective as of August 22, 2026 (the “Effective Date”)Director or officer change · Form 8-K
5. Aug 11, 2026On August 6, 2026, the Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) appointed Erik J. Bello, age 51, as the Company’s Vice President, Chief Accounting Officer, effective upon the commencement of his employment with the Company, which is expected to occur on August 31, 2026 (the “Effective Date”)Director or officer change · Form 8-K
6. Aug 4, 2026Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.Earnings release · press release
7. Jul 8, 2026On July 1, 2026, in connection with the closing of the Transaction (as defined in.Material agreement entered · Form 8-K
8. May 5, 2026Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029.Earnings release · press release
9. Apr 7, 2026On April 6, 2026, Ginger Zhou stepped down from her role as President of the Multiomics business of Azenta, Inc. (the “Company”). Dr. Zhou’s decision to step down was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.Director or officer change · Form 8-K
10. Apr 2, 2026As previously disclosed in the Company’s Current Report on Form 8-K filed on December 29, 2025, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc. (the “Company”), entered into a definitive Sale and Purchase Agreement with Thelema S.À R.L. (“Thelema”) relating to the sale of the entire issued share capital …Other event · Form 8-K
11. Mar 4, 2026On March 4, 2026, Azenta UK Ltd., a wholly owned subsidiary of Azenta, Inc. (“Azenta” or the “Company”) entered into a definitive Share Purchase Agreement (“Agreement”) under which Azenta UK Ltd. acquired all the issued and outstanding share capital of UK Biocentre Limited (“UK Biocentre”), a provider of sample …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.